CYP17 inhibition as a hormonal strategy for prostate cancer.
about
Emerging molecularly targeted therapies in castration refractory prostate cancerTrial watch - inhibiting PARP enzymes for anticancer therapyChloroquine and hydroxychloroquine for cancer therapyCastration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.New developments in the medical management of prostate cancer.CYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran.Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsMDV3100 for the treatment of prostate cancer.Novel therapies for metastatic castrate-resistant prostate cancer.Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.Androgen receptor antagonists in castration-resistant prostate cancer.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsNovel drugs targeting the androgen receptor pathway in prostate cancer.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerChanging paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesTaxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerA changing landscape in castration-resistant prostate cancer treatmentEvolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerContemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxelIntegrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.Therapeutic Approaches Targeting MYC-Driven Prostate CancerAbiraterone acetate for castration resistant prostate cancer.New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.Targeting 5α-reductase for prostate cancer prevention and treatmentNovel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingThe role of enzalutamide in the treatment of castration-resistant prostate cancer.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.Prostate cancer: beware of disseminated intravascular coagulation.
P2860
Q21284745-36200CA2-484A-487F-83FF-1FEE65F5325FQ26745673-BA1C8807-878C-4DA3-ADA4-1109106344F3Q26827797-CA04803C-BE72-41F4-9227-DD6C0A7287A8Q30495758-ABC40178-A1EB-47CC-84E8-652F77F291CCQ33566738-58A13830-687B-4268-A404-D08716532800Q33711108-6FD95753-A45E-47FF-8862-F3FE6B249FC1Q33845573-8A44BAA2-DF02-4053-8870-3E1299D90FABQ34141720-70B1B743-56C1-47BA-A09B-2463960F78BBQ34245740-75655756-75D6-4F25-BB72-A4CB5134FFC3Q34249263-B5248072-9084-4A96-BB20-C2852FC02124Q34310143-7AEDFFEF-CEF8-43B4-B677-80D12287DD59Q34323656-9826EBE9-F571-4A52-A300-EEAD1D96AE88Q34324736-DB2AB669-47A4-406E-8847-8273805DFE8EQ34395777-D49A43A2-AFF0-4AD9-908C-D6A389501983Q34619574-D9315A35-F79A-47BB-82E9-E8FC4C282F9CQ35210730-5016243E-BC44-42D2-87DA-73F77388BE1BQ35213324-17451EE4-7125-4EE1-91CD-1AA1C695FDDFQ35569303-023F9E1F-221F-468C-9CF8-BD3F2A1FF4A5Q35967139-CB1E15B8-696A-43ED-8B69-3D8284E810B2Q36101308-732CA387-2F5A-4404-886A-28E430B301D7Q36241242-0EBF8B2D-62CC-4D68-88E7-E2C3A503A271Q36294923-A117810D-D592-4F13-92E8-10040C72A2A3Q36316871-C4B30E74-21A7-405E-9965-6E3B3347EE3CQ36416408-02AF128A-D411-412F-A393-BD98666D3F0BQ36468744-2D06F102-75EB-401A-A47F-A2F7C84D4441Q36483161-957E18C6-5F78-4C34-8AE1-7A43FF837C50Q37443603-58D67630-7AE0-44D7-9866-7F91D86D26BEQ37564765-6A7D96FD-FA2E-4A98-AFA2-A1D5F9A0BCCEQ37676253-870B3182-4DEF-408C-B3C7-426D40B3AE0EQ37708308-93EE0D66-B0EE-4CB1-A32B-C92E97CBAEEAQ37762808-E3FB871A-585A-4572-90CD-234C22FF1D68Q37883012-71109F9A-37E3-49F5-AFD6-4ED6B476BC2DQ37952048-5D3EA6A3-8040-437C-8AB8-B1B6F3AA5B86Q38048881-ABB24EDC-BB5B-4B45-BF1F-95981111D74DQ38116358-C0842D43-EAEE-479A-B9BB-79EBCDAA9EE0Q38183819-6EDD57D0-4D3A-475B-976F-65043AC07926Q38184622-9C0D4023-4E8D-4D80-B61F-3AB6A27C6F15Q38785291-748B151A-889B-4B04-A791-53732B00C550Q38799227-A9B396FB-0373-4F45-8D13-93AE9C2EF597Q39265656-C6FD08F9-B06A-4D54-BCBE-D58F0D941CE4
P2860
CYP17 inhibition as a hormonal strategy for prostate cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
CYP17 inhibition as a hormonal strategy for prostate cancer.
@en
CYP17 inhibition as a hormonal strategy for prostate cancer.
@nl
type
label
CYP17 inhibition as a hormonal strategy for prostate cancer.
@en
CYP17 inhibition as a hormonal strategy for prostate cancer.
@nl
prefLabel
CYP17 inhibition as a hormonal strategy for prostate cancer.
@en
CYP17 inhibition as a hormonal strategy for prostate cancer.
@nl
P2093
P356
P1476
CYP17 inhibition as a hormonal strategy for prostate cancer
@en
P2093
Alison Hm Reid
Elaine Barrie
Johann S de Bono
P2888
P304
P356
10.1038/NCPURO1237
P407
P577
2008-11-01T00:00:00Z